Prof Mark Pritchard BSc, MBChB(hons), FRCP(UK), PhD

Professor Cellular and Molecular Physiology

Research

Gastrointestinal tumour development

My current research interests involves two main themes, firstly investigating the importance of apoptosis, inflammation and NFκB signalling in the pathogenesis of gastrointestinal diseases and secondly elucidating the importance of the gastrin family of peptides in the pathogenesis of gastric and colorectal neoplasms.

My research employs a wide range of techniques including cell lines, transgenic mouse models and biopsies from human patients. Primary organoids from mouse and human gastric epithelia are widely employed.

Research Grants

MECNUT: Impact of dietary exposure to emulsifiers on the intestinal mucosa - implications for inflammatory bowel disease and metabolic syndrome

MEDICAL RESEARCH COUNCIL (MRC)

November 2017 - September 2021

Investigating the impact of Streptococcus gallolyticus infection on epithelial cell turnover in an enteroid model

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

January 2017 - January 2018

Investigation of a novel gastrin receptor antagonist

TRIO MEDICINES LIMITED (UK)

October 2015 - September 2019

Targeting intestinal epithelial cell shedding using NF-kB inhibitors to ameliorate sepsis

FIONA ELIZABETH AGNEW TRUST (UK)

June 2016 - May 2017

Gastrin and C-Kit in Gastric Cancer.

ROYAL SOCIETY (CHARITABLE)

September 2000 - August 2001

Genetics of non-steroidal anti-inflammatory drugs (NSAIDs)-induced peptic ulceration: a genome wide association study.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

July 2010 - June 2011

Identification of patients at risk of gastric cancer

NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)

February 2014 - January 2015

Role of MMP-7 in the pathogenesis of gastric cancer.

NORTH WEST CANCER RESEARCH FUND

November 2003 - November 2006

The role of NF-kB and cell shedding in inflammatory Bowel Disease

WELLCOME TRUST (UK)

August 2011 - May 2014

Validation and exploitation of biomarkers for identification of patients at risk of gastric cancer

NORTH WEST CANCER RESEARCH FUND

November 2012 - October 2014

Development of primary cultures of human colonic epithelium.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

September 2005 - August 2007

Mechanisms of promotion of colorectal carcinogenesis by the non-amidated precursors of gastrin in vitro and in vivo.

NORTH WEST CANCER RESEARCH FUND

January 2001 - August 2004

Identification of patients at risk of gastric cancer due to helicobacter pylori infection

DEPARTMENT OF HEALTH (UK) (NIHR)

September 2007 - March 2012

Epithelial cell shedding induced gut barrier dysfunction

LIBYAN EMBASSY IN LONDON

October 2014 - September 2015

Role of NF-kappaB signalling in acute experimental pancreatitis

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

March 2014 - February 2015

Investigation of the mechanisms by which progastrin promotes colonic carcinogenesis.

NORTH WEST CANCER RESEARCH FUND

June 2006 - December 2010

Investigation of the intestinal microbiome of mice which have aberrant NF-kappaB signalling

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

August 2014 - July 2015

Bridging and accelerating the translation of novel scientific findings for health and wealth gain

MEDICAL RESEARCH COUNCIL (MRC)

March 2014 - August 2015

Investigation of the importance of individual members of the Nuclear Factor-kappaB (NF-kB) family during Helicobacter pylori-induced gastric carcinogenesis

WELLCOME TRUST (UK)

April 2008 - March 2011

Towards disease diagnosis through spectrochemical imaging of tissue architecture.

ENGINEERING & PHYSICAL SCIENCES RESEARCH COUNCIL (EPSRC)

June 2013 - September 2016

Assessment of the abundance of potential biomarkers of colorectal neoplasia in human patients

CANCER RESEARCH UK (CRUK) (UK)

July 2010 - September 2011

Importance of alternative pathway NF-κB signalling in Helicobacter-induced gastric carcinogenesis

NORTH WEST CANCER RESEARCH FUND

January 2013 - September 2016

How does the gastrin/CCK-2 receptor antagonist netazepide (YF476) alter gastric mucosal gene expression in patients with type I gastric neuroendocrine tumours?

UKI NETS (UK)

January 2014 - December 2014

The role of NF-kB and cell shedding in Inflammatory Bowel Disease.

WELLCOME TRUST (UK)

September 2009 - September 2012

Pathogenesis of type 1 gastric carcinoid tumours.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

September 2006 - August 2008

Investigation of the importance of the gastrin family of peptides and gastrin/CCKb receptor in inflammatory bowel disease.

NAT ASSOC FOR COLITIS & CROHNS DISEASE (UK)

September 2003 - September 2007

Systems medicine of chronic inflammatory bowel disease (SysmedIBD)

EUROPEAN COMMISSION

December 2012 - November 2017

Gastrin and its receptor inflammatory bowel disease.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

September 2003 - February 2007

Investigation of the genetic regulation of apoptosis in the stomach, with particular reference to the development of gastric atrophy.

WELLCOME TRUST (UK)

September 2002 - December 2007

Characterisation and assessment of the functional impact on gastric preneoplasia of the non-Helicobacter gastric dysbiosis of Nfkb1-/- and Nfkb2-/- mice

GUTS (UK CHARITY)

February 2014 - January 2015

How does the microbiome of the hypochlorhydric stomach promote gastric tumourigenesis?

WORLDWIDE CANCER RESEARCH (UK)

November 2012 - October 2015